An important goal of p-care is the use and expansion of the Interreg PreCanMed biobank.
The PreCanMed biobank is a biorepository of patient-derived tumor organoids and related molecular and drug sensitivity profiles.
It will be expanded with freshly collected samples from patients, including cancer cells, fibroblasts, endothelial cells, and immune cells. The expanded biobank will be the result of the collective effort of clinicians, cancer scientists, ‘omics’ and other technology experts, and bioinformaticians involved in the two Interreg projects.
Available specimens from the original biobank were collected from patients meeting inclusion criteria of the PreCanMed study. The collection includes chips of diseased and matched normal tissues from surgical resections of breast, lung and colon cancers.
A new observational study has been designed in the frame of p-care and approved by competent authorities. p-care will continue to collect tissue samples from primary tumors and metastases, and it will also collect other non-tumor cells from patients such as blood cells, fibroblasts, immune cells, endothelial cells, and others.
De-identified, sample matched datasets
Three categories of data are collected along with their related, banked material:
- patients’ clinical information on diagnosis, molecular and histopathology analyses, prescription drugs and treatments, as well as response to therapy;
- genomic data of selected patient-derived organoids ; and
- gene expression profiles of selected patient-derived organoids and spheroids.
Clinical data banked by PreCanMed and p-care are anonymised, ensuring patient privacy and confidentiality.
A resource for cancer research
A central goal of p-care is to make the expanded interreg biobank accessible to a broad scientific and medical community, to stimulate and speed up cross-border, as well as international cancer research.
How to gain access to data and biological material
Contact us to discuss possible collaborations.